Evaxion Unveils Preclinical Data for AI-Optimized CMV Vaccine Candidate — Evaxion A/S

Event summary

Evaxion will present preclinical data for its CMV vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026.
EVX-V1 combines AI-discovered antigens with optimized versions of established CMV vaccine antigens.
The data will guide final antigen selection for a broadly protective CMV vaccine.
CMV infects 60-70% of adults in developed countries and nearly 100% in developing economies.

The big picture

Evaxion's presentation highlights the growing intersection of AI and immunology in vaccine development. The company's approach to combining novel AI-discovered antigens with optimized traditional components addresses a significant unmet medical need, particularly for congenital CMV infections. With no approved CMV vaccine currently available, Evaxion's progress could position it as a key player in this underserved market.

What we're watching

Clinical Progress: Whether the preclinical data will accelerate EVX-V1's path to clinical trials and regulatory approval.
Market Opportunity: The pace at which Evaxion can capitalize on the growing CMV treatment market, projected to grow at 6.6% CAGR through 2032.
Competitive Positioning: How EVX-V1's multi-targeted strategy differentiates it from other CMV vaccine candidates in development.